Misplaced Pages

Velagliflozin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Medication

Pharmaceutical compound
Velagliflozin
Clinical data
Trade namesSenvelgo
License data
Routes of
administration		By mouth
ATCvet code
Legal status
Legal status
Identifiers
IUPAC name
  • 2--4-benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H25NO5
Molar mass395.455 g·mol
3D model (JSmol)
SMILES
  • C1CC1C2=CC=C(C=C2)CC3=C(C=CC(=C3)4((((O4)CO)O)O)O)C#N
InChI
  • InChI=1S/C23H25NO5/c24-11-17-8-7-16(23-22(28)21(27)20(26)19(12-25)29-23)10-18(17)9-13-1-3-14(4-2-13)15-5-6-15/h1-4,7-8,10,15,19-23,25-28H,5-6,9,12H2/t19-,20-,21+,22-,23+/m1/s1
  • Key:SENUNDCNOYAWGN-ZQGJOIPISA-N
  • Key:UWKBFNWQMSGEPG-ZHNCTCHCSA-N

Velagliflozin, sold under the brand name Senvelgo, is an antidiabetic medication used for the treatment of cats. Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It is taken by mouth.

Medical uses

Velagliflozin is indicated to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin.

References

  1. "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]". Health Canada. 18 October 2024. Retrieved 25 October 2024.
  2. ^ "Senvelgo- velagliflozin solution". DailyMed. 8 November 2023. Retrieved 13 December 2023.
  3. "Senvelgo Product information". Union Register of veterinary medicinal products. 22 November 2023. Retrieved 29 August 2024.
  4. ^ https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14320 Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ "Dear Veterinarian Letter regarding important safety conditions associated with the use of Senvelgo (velagliflozin oral solution) for improving glycemic control in certain cats with diabetes mellitus". U.S. Food and Drug Administration. 4 December 2023. Retrieved 13 December 2023. Public Domain This article incorporates text from this source, which is in the public domain.
Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)
Insulins / insulin analogs
fast-acting
short-acting
long-acting
ultra-long-acting
inhalable
  • Exubera
  • Afrezza
Non-insulins
Insulin sensitizers
Biguanides
TZDs/"glitazones" (PPAR)
Dual PPAR agonists
Amylin analogs and DACRAs
Secretagogues
KATP
Sulfonylureas
Meglitinides/"glinides"
GLP-1 receptor agonists
GLP1 poly-agonist peptides
DPP-4 inhibitors/"gliptins"
Other
Aldose reductase inhibitors
Alpha-glucosidase inhibitors
SGLT2 inhibitors/"gliflozins"
Other
Combinations
Sodium-glucose transporter modulators
SGLT1Tooltip Sodium-glucose transporter 1
SGLT2Tooltip Sodium-glucose transporter 2
SGLT1Tooltip Sodium-glucose transporter 1 & SGLT2Tooltip Sodium-glucose transporter 2
See also: Receptor/signaling modulators


Stub icon

This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: